ARIAD Pharmaceuticals Inc logo

ARIA - ARIAD Pharmaceuticals Inc News Story

$23.99 0.0  0.0%

Last Trade - 15/02/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £143.6m
Position in Universe th / 6408

Japan's Takeda expects annual sales of Ariad's lung cancer drug to exceed $1 bln

Tue 10th January, 2017 12:52am
TOKYO, Jan 10 (Reuters) - Japan's Takeda Pharmaceutical Co 
Ltd  4502.T  expects annual sales from new lung cancer drug 
brigatinib, added to its portfolio with the acquisition of Ariad 
Pharmaceuticals Inc  ARIA.O , will exceed $1 billion, the 
Japanese company's CEO said on Tuesday. 
    "It has the potential to be the best in class," Christophe 
Weber said during a conference after Takeda announced the $5.2 
billion acquisition of Ariad in a bid to boost its oncology 
pipeline.  urn:newsml:reuters.com:*:nL4N1EZ3G6 
     
 
 (Reporting by Tim Kelly; Editing by Michael Perry) 
 ((tim.kelly@thomsonreuters.com; +813-6441-1311;)) 
 
Keywords: ARIAD PHARM M&A/TAKEDA PHARMA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.